Letter to the editor
Mepolizumab for severe eosinophilic asthma – A one-year real life Portuguese study
R Brás1,
, M Paulino1, C Varandas, C Coutinho, MI Silva, R Limão, C Costa, E Alonso, E Pedro, A Mendes
Corresponding author
ritasabras@gmail.com
Corresponding author at: Immunoallergology Department, Hospital de Santa Maria – Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Corresponding author at: Immunoallergology Department, Hospital de Santa Maria – Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Immunoallergology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
Read
3960
Timeswas read the article
1785
Total PDF
2175
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 23 | 30 | 53 |
| 2025 5 | 100 | 46 | 146 |
| 2025 4 | 69 | 34 | 103 |
| 2025 3 | 65 | 39 | 104 |
| 2025 2 | 46 | 30 | 76 |
| 2025 1 | 35 | 37 | 72 |
| 2024 12 | 33 | 30 | 63 |
| 2024 11 | 49 | 44 | 93 |
| 2024 10 | 41 | 27 | 68 |
| 2024 9 | 42 | 23 | 65 |
| 2024 8 | 43 | 29 | 72 |
| 2024 7 | 44 | 33 | 77 |
| 2024 6 | 41 | 26 | 67 |
| 2024 5 | 40 | 31 | 71 |
| 2024 4 | 35 | 34 | 69 |
| 2024 3 | 54 | 26 | 80 |
| 2024 2 | 57 | 25 | 82 |
| 2024 1 | 30 | 21 | 51 |
| 2023 12 | 23 | 25 | 48 |
| 2023 11 | 47 | 44 | 91 |
| 2023 10 | 39 | 30 | 69 |
| 2023 9 | 32 | 37 | 69 |
| 2023 8 | 35 | 18 | 53 |
| 2023 7 | 27 | 31 | 58 |
| 2023 6 | 30 | 17 | 47 |
| 2023 5 | 36 | 35 | 71 |
| 2023 4 | 21 | 40 | 61 |
| 2023 3 | 39 | 32 | 71 |
| 2023 2 | 23 | 21 | 44 |
| 2023 1 | 19 | 21 | 40 |
| 2022 12 | 39 | 39 | 78 |
| 2022 11 | 46 | 37 | 83 |
| 2022 10 | 67 | 39 | 106 |
| 2022 9 | 44 | 41 | 85 |
| 2022 8 | 43 | 41 | 84 |
| 2022 7 | 45 | 50 | 95 |
| 2022 6 | 40 | 43 | 83 |
| 2022 5 | 42 | 39 | 81 |
| 2022 4 | 43 | 48 | 91 |
| 2022 3 | 34 | 54 | 88 |
| 2022 2 | 42 | 49 | 91 |
| 2022 1 | 60 | 51 | 111 |
| 2021 12 | 102 | 66 | 168 |
| 2021 11 | 181 | 82 | 263 |
| 2021 10 | 26 | 51 | 77 |
| 2021 9 | 18 | 39 | 57 |
| 2021 8 | 23 | 51 | 74 |
| 2021 7 | 62 | 49 | 111 |
Show all
